EMEA’s opinion to designate new orphan drugs
ORPHAN MEDICINAL PRODUCT DESIGNATION The COMP adopted six positive opinions recommending the following medicines for designation as orphan medicinal products to the European Commission: For the following medicines the EMEA review began on 12 September 2008 with an active review time of 90 days.